Can an immunotherapy boost standard treatment for a Head-and-Neck cancer?

NCT ID NCT06712888

Ongoing Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can improve outcomes for people with locally advanced nasopharyngeal carcinoma, a type of head-and-neck cancer. Participants will receive either toripalimab or a placebo alongside induction chemotherapy, followed by chemoradiation. The study aims to see if the combination improves progression-free survival and overall survival, and to compare safety between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab (an immunotherapy drug) combined with chemotherapy (gemcitabine and cisplatin) and radiation therapy
What this could lead to: If it works, this combination could slow or prevent cancer progression and improve survival for people with advanced nasopharyngeal carcinoma.
What could go wrong: This is an early-stage test in a specific patient group; results may not apply to all patients, and adding immunotherapy can increase immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA (NPC)

Contacts and locations

Locations

Affiliated Hospital of Guangdong Medical University

Zhanjiang, Guangdong, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

Shenzhen, Guangdong, China
First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China
Fujian Cancer Hospital

Fuzhou, Fujian, China
Guangxi Medical University Cancer Center

Nanning, Guangxi, China
Hunan Cancer Hospital

Changsha, Hunan, China
Sichuan Cancer Hospital

Chengdu, Sichuan, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The Affiliated Cancer Hosipital of Guizhou Meidical University

Guiyang, Guizhou, China
The University of Hong Kong-Shenzhen Hospital

Shenzhen, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.